SUBSCRIBE
SUBSCRIBE
News   Drug Development

ImmuPharma plc CEO Slams Stock Plunge After Drug Trial

November 19, 2009 | 
1 min read
Bookmark and Share

Reuters -- The head of lupus specialist ImmuPharma said mid-stage trial results for its lead drug were encouraging and should not have prompted a 19 percent drop in the share price on Thursday.
Clinical research Phase 2
MORE ON THIS TOPIC
Laptop with envelope and document with exclamation mark on screen. Receive notification, alert message, warning, get e-mail, email, spam concepts. Flat design vector illustration
FDA
UPDATE: FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy
July 27, 2026
 · 
3 min read
 · 
Heather McKenzie
Stacked person head silhouettes. Abstract painting.
Neuroscience
MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readout
July 27, 2026
 · 
2 min read
 · 
Michael Gibney
3D Paper Cut Pair of Lung dotted with yellow tumor bacteria infection spread across on a blue background with no text. Yellow dots as virus infection in the lungs. Vector Illustration.
Business
Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail
July 27, 2026
 · 
3 min read
 · 
Gabrielle Masson
Business competitive advantage of paper plane in new competitive, competitor individual pointing in different ways for new competitive advantage on 3D render. Advantage for new idea competition.
Insights
Denmark’s foundation‑fueled biotech boom redraws the Nordic map
July 27, 2026
 · 
4 min read
 · 
Jennifer C. Smith-Parker